

1 **Drug target Mendelian randomization supports apolipoprotein C3-lowering**
2 **for lipoprotein-lipid levels reductions and cardiovascular diseases prevention**

3

4

Eloi Gagnon, MA¹ and Benoit J. Arsenault, PhD^{1,2*}

5

6 1) Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec,
7 Québec (QC), Canada

8 2) Department of Medicine, Faculty of Medicine, Université Laval, Québec (QC), Canada

9

10

11 *Address for correspondence

12 Benoit Arsenault, PhD

13 Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec —

14 Université Laval

15 Y-3106, Pavillon Marguerite D'Youville, 2725 chemin Ste-Foy

16 Québec (QC), Canada G1V 4G5

17 Telephone: 418-656-8711 ext. 3498

18 Email: benoit.arsenault@criucpq.ulaval.ca

19

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Abstract

Background and aims: Inhibitors of apolipoprotein C-III (apoC3) are currently approved for the reduction of triglyceride levels in patients with Familial Chylomicronemia Syndrome. We used drug target Mendelian randomization (MR) to assess the effect of genetically predicted decrease in APOC3 blood protein levels on cardiometabolic traits and diseases.

Methods: We quantified lifelong reductions in APOC3 blood levels by selecting all genome wide significant and independent ($r^2 < 0.1$) single nucleotide polymorphisms (SNPs) in the *APOC3* gene region ± 1 Mb, from three genome-wide association studies (GWAS) of apoC3 blood protein levels (deCODE, $n = 35,378$, Fenland, $n = 10,708$ and ARIC, $n = 7,213$). We included the largest GWASes on 18 cardiometabolic traits and 9 cardiometabolic diseases as study outcomes.

Results: A one standard deviation lowering in apoC3 blood protein levels was associated with lower triglycerides, apolipoprotein B, density lipoprotein cholesterol, alanine aminotransferase, and glomerular filtration rate as well as higher high-density lipoprotein cholesterol levels. APOC3 lowering was also associated with lower risk of acute pancreatitis (odds ratio [OR] = 0.91 95% CI=0.82 to 1.00), aortic stenosis (OR = 0.82 95% CI=0.73 to 0.93), and coronary artery disease (OR = 0.86 95% CI=0.80 to 0.93), and was associated with increased parental lifespan (0.06 95% CI=0.03 to 0.09 years). These results were concordant across robust MR methods, the three protein datasets and upon adjustment for APOA1, APOA4 and APOA5 using a multivariable MR framework.

Conclusions: These results provide evidence that apoC3 lowering could result in widespread benefits for cardiometabolic health and encourage the launch of trials on apoC3 inhibition for coronary artery disease prevention.

48 **Introduction**

49
50 Apolipoprotein C-III (apoC3) is an established target for triglyceride lowering. ApoC3 reduction
51 by the antisense oligonucleotide (ASO) volanesorsen resulted in 77% lower circulating
52 triglyceride levels in individuals with the rare congenital syndrome Familial
53 Hyperchylomicronemia Syndrome (FCS) (Witztum et al. 2019). Beyond triglyceride lowering,
54 APOC3 could be implicated in the pathogenesis of other diseases (Giammanco et al. 2023),
55 opening potential opportunity for extending APOC3-ASO's indications for other more common
56 conditions.

57
58 Mounting genetic evidence support a causal role of apoC3 inhibition in the prevention of
59 cardiovascular diseases. *APOC3* heterozygous loss of function mutations carrier have on average
60 40% lower plasma triglyceride levels and a 46% lower coronary heart disease risk in the exome
61 sequencing project (498 carriers vs. 110,472 non-carriers) (The TG and HDL Working Group of
62 the Exome Sequencing Project 2014) and 36% lower risk of ischemic heart disease in the
63 Copenhagen General Population Study (302 carriers, 75,423 non-carriers) (Jørgensen et al.
64 2014). Akin to studies on loss of function carriers, mendelian randomization (MR) studies
65 leverage naturally occurring genetic variations to investigate the impact of perturbing drug
66 targets on health outcomes (Gill and Burgess 2022). These genetic variations are randomly
67 distributed during meiosis and remain constant throughout life, making MR results unlikely to be
68 influenced by confounding factors or reverse causality. Drug target MR study designs may also
69 help identify new indications for existing drugs, predict randomized clinical trial (RCT)
70 outcomes, and identify ontarget adverse effects (Gill and Burgess 2022). MR studies on apoC3
71 have proven challenging as this protein is encoded by a complex genetic locus on chromosome
72 11 harboring other genes influencing lipoprotein metabolism such as *APOA1*, *APOA4*, and
73 *APOA5*. However, recent advances in large-scale proteo-genetics can help isolate genetically
74 predicted apoC3 blood concentrations from these other apolipoproteins opening the door to drug
75 target MR studies on apoC3 genetic inhibition.

76
77 Here, we performed drug target MR analyses evaluating the effect of genetically predicted lower
78 apoC3 protein levels on CAD as well as 8 other cardiometabolic diseases and 18 cardiometabolic

79 traits. We show that genetically predicted apoC3 reduction is associated with a healthier
80 metabolic profile as well as a lower risk of CAD, aortic stenosis and acute pancreatitis.

81

82

83

Methods

84

Genome-wide association studies on blood protein levels

85
86 The datasets used to derive the study exposures and outcomes are presented Supplementary
87 Table 1. We included three distinct population-based cohorts for genetic-plasma protein levels
88 associations: deCODE, Atherosclerosis Risk in Communities (ARIC), and Fenland (Ferkingstad
89 et al. 2021; Zhang et al. 2022; Pietzner et al. 2021). 1) In the deCODE cohort, plasma protein
90 levels were measured in 35,365 Icelanders. These measurements were adjusted for age and sex
91 and the resulting residuals were inverse rank normal transform prior to GWAS. Genotyping was
92 performed using Illumina SNP chips. 2) In the ARIC population-based cohort, protein plasma
93 levels were measured in 7,213 European Americans. These measurements were adjusted in a
94 linear regression model including PEER factors and the covariates sex, age, study site, and 10
95 ancestry-based principal components. Genotyping was performed using Illumina SNP chips. 3)
96 In the Fenland population-based cohort, protein plasma levels were measured in 10,708
97 European-descent participants. These measurements were adjusted for age, sex, the first ten
98 principal components of ancestry and the test sites. The resulting residuals were inverse rank
99 normal transform prior to GWAS. Fenland participants were genotyped using three genotyping
100 arrays: the Affymetrix UK 1149 Biobank Axiom array (OMICs, n=8994), Illumina Infinium
101 Core Exome 24v1 (Core-Exome, 1150 n=1060) and Affymetrix SNP5.0 (GWAS, n=1402).
102 Primary analyses were performed using the deCODE cohort because this study had the largest
103 sample size.

104

Cardiometabolic traits and outcomes genome-wide association studies

105
106 Relevant information on the GWAS summary statistics used throughout this study is presented in
107 Supplementary Table 1. Parental lifespan, fasting glucose, fasting insulin, and glomerular
108 filtration rate were reported in years, log(pmol/L), log(pmol/L) and log(eGFR) respectively. For
109 better interpretability and comparability, we transformed these summary statistics to a one

110 standard deviation scale using the `sdY.est` function in the `coloc` package (Wallace 2020). The
111 other continuous variables were already inverse-rank normal transformed in the GWAS.

112

113 Genetic variant selection and harmonisation

114 We identified common variants (minor allele frequency > 0.01) within a 1 Mb window around
115 the gene region associated ($p < 5e-8$) with lower blood protein levels in the ARIC (N= 7,213),
116 deCODE (N= 35,365) or Fenland (N= 10,708) population-based cohort. Variants were then
117 clumped respectively to the lowest p-value of any of these cohorts (linkage disequilibrium r^2
118 <0.1 and window = 10 MB). When a SNP alter the structure of a protein, the statistical
119 association between that SNP and protein levels may be biased, a phenomenon known as epitope
120 binding artifact . To prevent epitope binding artifacts, these SNPs were annotated using the
121 variant effect predictor (McLaren et al. 2016). We removed every SNPs tagged as being
122 missense variant, stop gained, stop lost, start gained, start lost, or frameshift. The strength of
123 every instrument was evaluated with the Cragg-Donald F-statistic (Stephen Burgess, Thompson,
124 and CRP CHD Genetics Collaboration 2011). Variant harmonization was performed by aligning
125 the betas of different studies on the same effect allele with the *TwoSampleMR* V.0.5.6 package
126 (Hemani et al. 2018). When a particular exposure SNP was not present in the outcome dataset,
127 we used proxy SNPs instead ($R^2 > 0.8$). We used the LD matrix of the 1000 Genomes Project -
128 European sample of the Utah residents from North and West Europe.

129

130 Mendelian randomization analyses

131 For univariable primary MR analyses, we performed the inverse variance weighted (IVW)
132 method with multiplicative random effects (Stephen Burgess, Foley, and Zuber 2018). MR must
133 respect three core assumptions (relevance, independence and exclusion restriction) for valid
134 causal inference. Failure to respect these assumptions can occur if the genetic instruments
135 influence several traits on different causal pathways. This phenomenon, referred to as horizontal
136 pleiotropy, can be balanced by applying robust MR methods (Slob and Burgess 2020). To verify
137 if pleiotropy likely influenced the primary univariable MR results, we performed four different
138 robust MR analyses: the MR Egger intercept test (Bowden, Davey Smith, and Burgess 2015), the
139 contamination mixture (Stephen Burgess et al. 2020), the weighted median, and the MR-
140 PRESSO (Verbanck et al. 2018), each making a different assumption about the underlying nature

141 of the pleiotropy. Consistent estimates across methods provide further confirmation about the
142 nature of the causal links. An intercept not significantly different from zero in the Egger test
143 support that pleiotropy is balance (Bowden, Davey Smith, and Burgess 2015). Univariable MR
144 analyses were performed using the *TwoSampleMR* V.0.5.6 package (Hemani et al. 2018).

145

146 Multivariable Mendelian randomization analyses

147 For multivariable primary MR analysis, we conducted the IVW method (S. Burgess and
148 Thompson 2015). As robust MVMR analyses, we used the multivariable MR-Egger (Rees,
149 Wood, and Burgess 2017), the multivariable median method, and the multivariable MR-Lasso
150 method (Grant and Burgess 2021). Akin to robust univariable MR analyses, each method makes
151 different assumptions about the underlying nature of the pleiotropy so that consistent estimates
152 give confidence in the robustness of the causal finding. Multivariable MR analyses were
153 performed using the *MendelianRandomization* V.0.9.0 package (Yavorska and Burgess 2017).
154 To estimate instrument strength given the other exposures included in the model, we calculated
155 conditional F statistics (Sanderson, Spiller, and Bowden 2021).

156

157

158 **Results**

159

160 We identified up to 15 genetic proxies for apoC3 levels, explaining 3% of the variance in
161 APOC3 levels (Supplementary Table 2 and Supplementary Table 3). Lower genetically predicted
162 APOC3 plasma levels were associated with lower triglyceride levels (effect size per 1 SD
163 [standard deviation] lower apoC3 plasma levels = -0.77 95% CI=-0.99 to -0.55, p=6.4e-12). This
164 result was directionally consistent and maintained statistical significance (p-value < 0.05) across
165 all robust MR approaches (weighted median, weighted mode, contamination mixture, MR-
166 PRESSO) (Supplementary Table 4) and Egger intercept did not differ from zero (Supplementary
167 Table 5). This result was similar across the other study cohorts. Altogether, these results
168 corroborate RCT findings with RNA interference therapy targeted at *APOC3* providing
169 validation for the genetic instrument.

170

171 MR analyses were consistent with apoC3 lowering being associated with a more favorable
172 cardiometabolic risk profile. Genetically instrumented predicted apoC3 lowering was associated
173 with lower apoB levels (-0.20 95% CI=-0.27 to -0.12, p=1.3e-06), lower LDL cholesterol levels
174 (-0.16 95% CI=-0.22 to -0.11, p=4.2e-09), lower aspartate amino transferase (-0.08 95% CI=-
175 0.13 to -0.04, p=5.9e-05), lower alanine amino transferase (-0.04 95% CI=-0.06 to -0.02, p=2.6e-
176 05) and higher HDL cholesterol levels (0.37 95% CI= 0.27 to 0.47, p=5.0e-14, Figure 1). There
177 was robust evidence of a small negative effect on glomerular filtration rate (-0.02 95% CI=-0.03
178 to 0.00, p=6.1e-03). There was nominal evidence for an association with fasting glucose, but not
179 reaching statistical significance in robust MR analyses.

180

181 MR analyses were consistent with protective associations of genetically predicted apoC3
182 lowering with risk of aortic stenosis (OR per 1 SD reduction in APOC3 levels 0.82 95% CI=0.73
183 to 0.93, p=1.3e-03), and CAD (OR = 0.86 95% CI=0.80 to 0.93, p=4.2e-05, Figure 2). There was
184 nominal evidence for an association with acute pancreatitis and heart failure but not reaching
185 statistical significance in robust MR analyses. There was no evidence for an association with
186 non-alcoholic fatty liver disease, type 2 diabetes, chronic kidney disease, Alzheimer's disease, or
187 stroke. There was evidence for an association with longer life expectancy (0.06 years 95% CI=
188 0.03 to 0.09, p=1.4e-05).

189

190 The human *APOC3* gene is located on chromosome 11 in a cluster with three other
191 apolipoprotein genes, *APOA1*, *APOA4*, and *APOA5*. The genetic variants used to proxy apoC3
192 levels may also be associated with pleiotropic pathway through the levels of these
193 apolipoproteins. We performed multivariable MR analyses, adjusting for genetic associations
194 with apoA1, apoA4 and apoA5 plasma protein levels in the same cohort. We extracted the
195 genetic instruments for these proteins using the same genetic instrument selection procedure as
196 for *APOC3*. We then pooled these SNPs to the lowest p-value of any of the exposures, using the
197 same parameter setting as the univariable MR ($r^2=0.1$, window=1 Mb), resulting in 65 SNPs.
198 Conditional F statistics were 20 for apoA1, 4 for apoA4, 89 for apoA5, and 5 for apoC3,
199 indicating adequate instrument strength. Adjustment for genetic associations with serum apoA1,
200 apoA4 and apoA5 did not influence the direction or the significance of the MR estimates
201 (Supplementary Table 6). Adjustment for these apolipoproteins did not affect the results. For

202 example, genetically predicted apoC3 lowering was associated with a 0.77 SD decrease in
203 triglycerides without adjustment, and a similar 0.77 SD decrease in triglycerides with adjustment
204 (Figure 3). ApoC3 was similarly associated to CAD with and without adjustment (Figure 4).

205

206 It is plausible that the effect of apoC3 lowering on the occurrence of diseases is linked to its
207 influence on lipids. Specifically, triglycerides are a known causal factor of acute pancreatitis,
208 while apoB is a known causal factor of coronary artery disease. To shed lights on the underlying
209 mechanism, we used a multivariable MR approach (Figure 5, Supplementary Table 7). For this
210 analysis, we included the genetic proxies of apoC3 identified in the univariable analysis as
211 instrumental variables. When adjusting for triglyceride levels, apoC3 was no longer associated
212 with acute pancreatitis. Similarly, when adjusting for apoB levels, the association between
213 APOC3 and CAD was null. In contrast, when adjusting for either apoB or triglycerides, apoC3
214 remained associated with aortic stenosis, although the association did not reach statistical
215 significance. These results support that the effect of apoC3 on CAD and acute pancreatitis is
216 entirely explained by the effect on apoB and triglyceride levels. ApoC3 may have a direct effect
217 on aortic stenosis, not mediated through its impact on lipoprotein-lipid levels.

218

219

220

Discussion

221

222 We performed drug target Mendelian randomization to determine the effect of genetically
223 predicted apoC3 lowering on cardiometabolic health. Our results show that genetically predicted
224 apoC3 lowering was associated with lower circulating levels of triglycerides, apoB, LDL
225 cholesterol, alanine amino transferase, aspartate amino transferase, and higher circulating
226 levels of HDL cholesterol. Furthermore, genetically predicted apoC3 lowering was associated
227 with lower risk of CAD and aortic stenosis and to a smaller extent acute pancreatitis. These
228 associations were concordant across three large blood pQTL datasets, concordant with robust
229 MR methods and concordant in multivariable MR when including genetic information for
230 apoA1, apoA4 and apoA5. Altogether, these results provide genetic evidence that apoC3 may
231 represent a therapeutic target of interest to improve cardiometabolic health.

232

233 Most of our MR results are in line with results from RCTs on apoC3 lowering and extent those
234 results to show that apoC3 reductions may provide cardiovascular benefits. A clinical trial
235 involving patients with hypertriglyceridemia found that administering the ASO against *APOC3*
236 olezarsen 50 mg every four weeks significantly lowered apoC3 by 74%, triglycerides by 23%,
237 apoB by 10%, but no effect on lipoprotein(a) levels when compared to a placebo after 6 months
238 of treatment (Tardif et al. 2022). Similarly, In a phase 1/2a study in healthy volunteers (ages 18–
239 65) without elevated triglyceride levels, administration of olezarsen every four weeks for three
240 months resulted in a median reduction of circulating apoC3 of 89%, circulating triglycerides of
241 66%, circulating ApoB of 20%, and increase in HDL cholesterol of 60% observed immediately
242 after the first injection and maintained throughout the treatment (Alexander et al. 2019). These
243 concordant results provide external validation for our genetic instrument proxying lifelong
244 *APOC3* perturbation.

245

246 The ASO against liver *APOC3*, volanorsen, is approved in the European Union for FCS (Paik
247 and Duggan 2019). In this patient population, volanorsen reduced triglycerides by 77% when
248 compared to placebo (Witztum et al. 2019). By doing so, Volanorsen could help reduce the rate
249 of acute pancreatitis. Observational data suggest that the incidence of acute pancreatitis increases
250 approximately 3% for every increment of 100mg/dl in triglyceride levels over 1000 mg/dl
251 (Rashid et al. 2016). In our MR study, genetically predicted *APOC3* lowering was associated
252 with lower acute pancreatitis risk, although this association did not survive more robust MR
253 analyses. Multivariable MR supported that this effect was presumably entirely explained by
254 triglyceride levels. Although our MR analysis was not performed in the FCS population, these
255 results provide genetic support to potential benefits of apoC3 lowering in acute pancreatitis
256 prevention.

257

258 Heterozygous carriers of rare loss of function mutation in *APOC3* were found to have 40% lower
259 plasma triglyceride levels and a comparable lower CAD event rate (The TG and HDL Working
260 Group of the Exome Sequencing Project 2014). Our findings indicate that CAD risk in the
261 general population is influenced by apoC3 levels, not only apoC3 activity. Our multivariable MR
262 results also suggest that the impact of apoC3 lowering is primarily driven by its influence on
263 apoB. Whether apoC3 inhibitors could provide cardiovascular protection in patients with

264 elevated triglyceride levels at high residual CVS risk will ultimately need to be determined in a
265 large cardiovascular outcomes RCT.

266

267 Our MR results also suggest that apoC3 may have a role in the development of aortic stenosis.

268 Aortic stenosis is characterised by thickening, fibrosis, and mineralization of the aortic valve

269 leaflets (Moncla et al. 2023). Currently, there are no pharmacological therapy available to

270 prevent or slow its progression. Surgical valve replacement remains the only treatment option.

271 ApoC3 is present in aortic valve leaflets, as reported in a study by Capoulade et al. in 2020

272 (Capoulade et al. 2020). In this study, elevated levels of ApoC3-Lipoprotein(a) complexes have

273 been shown to predict rapid hemodynamic progression of aortic stenosis in patients with mild to

274 moderate aortic stenosis. High circulating levels of Lipoprotein(a) is an established causal factor

275 for aortic stenosis (Arsenault et al. 2014; Thanassoulis et al. 2013). Our study results show that

276 genetically predicted apoC3 lowering is associated with lower aortic stenosis risk but is not

277 associated with lipoprotein(a) levels. These findings suggest that apoC3 may elevate the risk of

278 aortic stenosis, but it does so independently of any impact on lipoprotein(a) levels. As an

279 important proportion of the apoC3-aortic stenosis relation was mediated with lipoprotein-lipid

280 levels, ApoC3 could represent an interesting therapeutic target for the prevention or treatment of

281 aortic stenosis in patients with elevated triglyceride levels.

282

283 The main strength of the present study is the use of a MR study design using multiple robust and

284 independent cis-acting instruments, minimizing the likelihood of horizontal pleiotropy. A second

285 strength is the use of multiple study cohorts to derive the genetic proxies improving robustness.

286 Our study findings must be evaluated within three main study limitations. First, genetic data was

287 restricted for individuals of European ancestry to reduce chances of type 1 error due to

288 population stratification, so the generalisability of the study's findings to other populations is

289 uncertain, especially in the context of other studies documenting a role of apoC3 in other ethnic

290 groups (Saleheen et al. 2017). Second, MR evaluates lifelong effect of a genetically perturbed

291 target, but trials often start later in life and for a shorter duration. Therefore, drug target MR

292 typically estimates stronger causal effects compared to RCTs. Finally, we could only evaluated

293 on-target effect of apoC3 lowering. Potential off-target effects of existing drug targeting APOC3

294 are not captured by our study design.

295
296 In conclusion, these results support that lowering of apoC3 blood protein levels may have several
297 cardiometabolic health benefits such as a reduction in the risk of CAD, aortic stenosis and
298 potentially acute pancreatitis and increased lifespan. RNA interference therapies effectively
299 lowering apoC3 are already approved for the treatment of FCS. These findings provide genetic
300 support and a rationale for the launch of cardiovascular outcomes RTCs on long-term apoC3
301 inhibition.

304 **Declarations**

306 Institutional Review Board Approval

307 All data used in this study are in the public domain. All participants provided informed consent
308 and study protocols were approved by their respective local ethical committees. This project was
309 approved by the Institutional Review Board of the Quebec Heart and Lung Institute.

310 Data Availability

311 All data used in this study are in the public domain. Supplementary Table 1 describes the data
312 used and relevant information to retrieve the summary statistics.

313 Code Availability

314 Code to reproduce the results of this manuscript is available on
315 <https://github.com/gagelo01/APOC3>

316 Competing interests

317 BJA is a consultant for Novartis, Eli Lilly, Editas Medicine and Silence Therapeutics and has
318 received research contracts from Pfizer, Eli Lilly and Silence Therapeutics.

319 Funding

320 EG holds a doctoral research award from the *Fonds de recherche du Québec: Santé*. (FRQS).
321 BJA holds a senior scholar awards from the FRQS.

322 Acknowledgements

323 We would like to thank all study participants as well as all investigators of the studies that were
324 used throughout the course of this investigation.

325 Authors' contributions

326 Data acquisition and analysis EG. Conception and design EG, BJA. Drafting of the work EG,
327 BJA. Both authors approved the final version of the manuscript.

328

329

330

331

References

332

333 Arsenault, Benoit J., S. Matthijs Boekholdt, Marie-Pierre Dubé, Eric Rhéaume, Nicholas J.
334 Wareham, Kay-Tee Khaw, Manjinder S. Sandhu, and Jean-Claude Tardif. 2014.
335 ‘Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis: A Prospective
336 Mendelian Randomization Study and Replication in a Case-Control Cohort’. *Circulation.
337 Cardiovascular Genetics* 7 (3): 304–10.
338 <https://doi.org/10.1161/CIRCGENETICS.113.000400>.

339 Bowden, Jack, George Davey Smith, and Stephen Burgess. 2015. ‘Mendelian Randomization
340 with Invalid Instruments: Effect Estimation and Bias Detection through Egger
341 Regression’. *International Journal of Epidemiology* 44 (2): 512–25.
342 <https://doi.org/10.1093/ije/dyv080>.

343 Burgess, S., and S. G. Thompson. 2015. ‘Multivariable Mendelian Randomization: The Use of
344 Pleiotropic Genetic Variants to Estimate Causal Effects’. *American Journal of
345 Epidemiology* 181 (4): 251–60. <https://doi.org/10.1093/aje/kwu283>.

346 Burgess, Stephen, Christopher N. Foley, Elias Allara, James R. Staley, and Joanna M. M.
347 Howson. 2020. ‘A Robust and Efficient Method for Mendelian Randomization with
348 Hundreds of Genetic Variants’. *Nature Communications* 11 (1): 376.
349 <https://doi.org/10.1038/s41467-019-14156-4>.

350 Burgess, Stephen, Christopher N. Foley, and Verena Zuber. 2018. ‘Inferring Causal
351 Relationships Between Risk Factors and Outcomes from Genome-Wide Association
352 Study Data’. *Annual Review of Genomics and Human Genetics* 19 (August): 303–27.
353 <https://doi.org/10.1146/annurev-genom-083117-021731>.

354 Burgess, Stephen, Simon G. Thompson, and CRP CHD Genetics Collaboration. 2011. ‘Avoiding
355 Bias from Weak Instruments in Mendelian Randomization Studies’. *International
356 Journal of Epidemiology* 40 (3): 755–64. <https://doi.org/10.1093/ije/dyr036>.

357 Ferkingstad, Egil, Patrick Sulem, Bjarni A. Atlason, Gardar Sveinbjornsson, Magnus I.
358 Magnusson, Edda L. Styrnisdottir, Kristbjorg Gunnarsdottir, et al. 2021. ‘Large-Scale
359 Integration of the Plasma Proteome with Genetics and Disease’. *Nature Genetics* 53 (12):
360 1712–21. <https://doi.org/10.1038/s41588-021-00978-w>.

361 Gill, Dipender, and Stephen Burgess. 2022. ‘The Evolution of Mendelian Randomization for
362 Investigating Drug Effects’. *PLOS Medicine* 19 (2): e1003898.
363 <https://doi.org/10.1371/journal.pmed.1003898>.

364 Grant, Andrew J., and Stephen Burgess. 2021. ‘Pleiotropy Robust Methods for Multivariable
365 Mendelian Randomization’. *Statistics in Medicine*, August.
366 <https://doi.org/10.1002/sim.9156>.

367 Hemani, Gibran, Jie Zheng, Benjamin Elsworth, Kaitlin H Wade, Valeria Haberland, Denis
368 Baird, Charles Laurin, et al. 2018. ‘The MR-Base Platform Supports Systematic Causal

- 369 Inference across the Human Phenome'. *eLife* 7 (May): e34408.
370 <https://doi.org/10.7554/eLife.34408>.
- 371 McLaren, William, Laurent Gil, Sarah E. Hunt, Harpreet Singh Riat, Graham R. S. Ritchie, Anja
372 Thormann, Paul Flicek, and Fiona Cunningham. 2016. 'The Ensembl Variant Effect
373 Predictor'. *Genome Biology* 17 (1): 122. <https://doi.org/10.1186/s13059-016-0974-4>.
- 374 Moncla, Louis-Hippolyte Minvielle, Mewen Briend, Yohan Bossé, and Patrick Mathieu. 2023.
375 'Calcific Aortic Valve Disease: Mechanisms, Prevention and Treatment'. *Nature Reviews*
376 *Cardiology* 20 (8): 546–59. <https://doi.org/10.1038/s41569-023-00845-7>.
- 377 Paik, Julia, and Sean Duggan. 2019. 'Volanesorsen: First Global Approval'. *Drugs* 79 (12):
378 1349–54. <https://doi.org/10.1007/s40265-019-01168-z>.
- 379 Pietzner, Maik, Eleanor Wheeler, Julia Carrasco-Zanini, Adrian Cortes, Mine Koprulu, Maria A.
380 Wörheide, Erin Oerton, et al. 2021. 'Mapping the Proteo-Genomic Convergence of
381 Human Diseases'. *Science (New York, N.Y.)* 374 (6569): eabj1541.
382 <https://doi.org/10.1126/science.abj1541>.
- 383 Rashid, Nazia, Puza P. Sharma, Ronald D. Scott, Kathy J. Lin, and Peter P. Toth. 2016. 'Severe
384 Hypertriglyceridemia and Factors Associated with Acute Pancreatitis in an Integrated
385 Health Care System'. *Journal of Clinical Lipidology* 10 (4): 880–90.
386 <https://doi.org/10.1016/j.jacl.2016.02.019>.
- 387 Rees, Jessica M. B., Angela Wood, and Stephen Burgess. 2017. 'Extending the MR-Egger
388 Method for Multivariable Mendelian Randomization to Correct for Both Measured and
389 Unmeasured Pleiotropy'. *arXiv:1708.00272 [Stat]*, August.
390 <http://arxiv.org/abs/1708.00272>.
- 391 Saleheen, Danish, Pradeep Natarajan, Irina M. Armean, Wei Zhao, Asif Rasheed, Sumeet A.
392 Khetarpal, Hong-Hee Won, et al. 2017. 'Human Knockouts and Phenotypic Analysis in a
393 Cohort with a High Rate of Consanguinity'. *Nature* 544 (7649): 235–39.
394 <https://doi.org/10.1038/nature22034>.
- 395 Sanderson, Eleanor, Wes Spiller, and Jack Bowden. 2021. 'Testing and Correcting for Weak and
396 Pleiotropic Instruments in Two-Sample Multivariable Mendelian Randomization'.
397 *Statistics in Medicine* 40 (25): 5434–52. <https://doi.org/10.1002/sim.9133>.
- 398 Slob, Eric A. W., and Stephen Burgess. 2020. 'A Comparison of Robust Mendelian
399 Randomization Methods Using Summary Data'. *Genetic Epidemiology* 44 (4): 313–29.
400 <https://doi.org/10.1002/gepi.22295>.
- 401 Tardif, Jean-Claude, Ewa Karwatowska-Prokopczuk, Eric St Amour, Christie M Ballantyne,
402 Michael D Shapiro, Patrick M Moriarty, Seth J Baum, et al. 2022. 'Apolipoprotein C-III
403 Reduction in Subjects with Moderate Hypertriglyceridaemia and at High Cardiovascular
404 Risk'. *European Heart Journal* 43 (14): 1401–12.
405 <https://doi.org/10.1093/eurheartj/ehab820>.
- 406 Thanassoulis, George, Catherine Y. Campbell, David S. Owens, J. Gustav Smith, Albert V.
407 Smith, Gina M. Peloso, Kathleen F. Kerr, et al. 2013. 'Genetic Associations with
408 Valvular Calcification and Aortic Stenosis'. *New England Journal of Medicine* 368 (6):
409 503–12. <https://doi.org/10.1056/NEJMoa1109034>.
- 410 The TG and HDL Working Group of the Exome Sequencing Project. 2014. 'Loss-of-Function
411 Mutations in APOC3, Triglycerides, and Coronary Disease'. *The New England Journal*
412 *of Medicine* 371 (1): 22–31. <https://doi.org/10.1056/NEJMoa1307095>.
- 413 Verbanck, Marie, Chia-Yen Chen, Benjamin Neale, and Ron Do. 2018. 'Detection of
414 Widespread Horizontal Pleiotropy in Causal Relationships Inferred from Mendelian

- 415 Randomization between Complex Traits and Diseases’. *Nature Genetics* 50 (5): 693–98.
416 <https://doi.org/10.1038/s41588-018-0099-7>.
- 417 Witztum, Joseph L., Daniel Gaudet, Steven D. Freedman, Veronica J. Alexander, Andres
418 Digenio, Karren R. Williams, Qingqing Yang, et al. 2019. ‘Volanesorsen and
419 Triglyceride Levels in Familial Chylomicronemia Syndrome’. *New England Journal of*
420 *Medicine* 381 (6): 531–42. <https://doi.org/10.1056/NEJMoa1715944>.
- 421 Yavorska, Olena O., and Stephen Burgess. 2017. ‘MendelianRandomization: An R Package for
422 Performing Mendelian Randomization Analyses Using Summarized Data’. *International*
423 *Journal of Epidemiology* 46 (6): 1734–39. <https://doi.org/10.1093/ije/dyx034>.
- 424 Zhang, Jingning, Diptavo Dutta, Anna Köttgen, Adrienne Tin, Pascal Schlosser, Morgan E.
425 Grams, Benjamin Harvey, et al. 2022. ‘Plasma Proteome Analyses in Individuals of
426 European and African Ancestry Identify Cis-pQTLs and Models for Proteome-Wide
427 Association Studies’. *Nature Genetics* 54 (5): 593–602. [https://doi.org/10.1038/s41588-](https://doi.org/10.1038/s41588-022-01051-w)
428 [022-01051-w](https://doi.org/10.1038/s41588-022-01051-w).
- 429
- 430

Figure Legends

Figure 1. Effect of one standard deviation reduction in genetically predicted APOC3 blood protein levels on 18 cardiometabolic traits. Standard deviation change per one standard deviation increase with 95% confidence intervals are shown. P-values correspond to two-sided tests for the inverse variance weighted method with random effect model.

Figure 2. Effect of one standard deviation reduction in genetically predicted APOC3 blood protein levels on 9 cardiometabolic outcomes. Odds ratios per standard deviation with 95% confidence intervals are shown. P-values correspond to two-sided tests for the inverse variance weighted method with random effect model.

Figure 3. Effect of apolipoproteins in the APOA1/A4/A5/C3 gene cluster on triglycerides using univariable and multivariable Mendelian randomization. Standard deviation change per one standard deviation increase with 95% confidence intervals are shown. P-values correspond to two-sided tests. For univariable MR the IVW with random effect model was used. For multivariable MR, the multivariable IVW was used.

Figure 4. Effect of apolipoproteins in the APOA1/A4/A5/C3 gene cluster on coronary artery disease using univariable and multivariable Mendelian randomization. Odds ratios per standard deviation with 95% confidence intervals are shown. P-values correspond to two-sided tests. For univariable MR the IVW with random effect model was used. For multivariable MR, the multivariable IVW was used.

Figure 5. Effect of APOC3 on coronary artery disease, aortic stenosis, and acute pancreatitis before and after adjustment for triglycerides or apolipoprotein B levels using multivariable Mendelian randomization. Odds ratios per standard deviation with 95% confidence intervals are shown. P-values correspond to two-sided tests of the multivariable IVW analysis.




Figure 1.




Figure 2.




Figure 3.




Figure 4.




Figure 5.